Search bioRxiv⌕ Search

Biology subjects

Franzoso, G.

Publications and source records attributed to Franzoso, G..

2 recordsLinked to original sources

Lipid droplet accumulation drives glutamine-dependent NLRP3 inflammasome activation

The NLRP3 inflammasome is implicated in the pathogenesis of many inflammatory and metabolic diseases. Although metabolic cues can shape NLRP3 inflammasome activation, the role of lipid metabolism in this response is poorly understood. Lipids are essential for energy and redox homeostasis, membrane biogenesis, and diverse cellular processes. However, excessive accumulation of lipids such as free fatty acids can be highly cytotoxic. Consequently, surplus free fatty acids are esterified into triglycerides and cholesteryl esters, which are then stored within lipid droplets (LDs). Interestingly, transcriptomic data analyses revealed that macrophages exposed to inflammasome-activating stimulus undergo a broad metabolic rewiring favouring lipid storage, suggesting a link between LDs and inflammasome response. Here, we show that LD accumulation actively promotes NLRP3 inflammasome activation. Increasing LD abundance, either by fatty acid supplementation or by inhibition of lipolysis, led to robust caspase-1 activation and IL-1{beta} release both in vitro and in vivo. Mechanistically, LD expansion promoted cellular reorganisation resulting in the formation of peri-droplet mitochondria, a distinct mitochondrial subpopulation which exhibited elevated membrane potential and increased ATP-linked respiration. Furthermore, LD-rich macrophages underwent metabolic reconfiguration whereby they exhibited a pronounced reliance on pyruvate and glutamine metabolism, but not fatty acid oxidation, to sustain mitochondrial bioenergetics. Surprisingly, inflammasome activation was found dependent predominantly on glutaminolysis, highlighting a key role for glutamine catabolism in LD-rich cells. Collectively, these findings identify a glutamine-dependent pathway as a key driver linking excess lipid storage to NLRP3 inflammasome, with profound implications in metabolic diseases.

immunology↗

Co-activation of NF-κB and MYC renders cancer cells addicted to IL6 for survival and phenotypic stability

NF-{kappa}B and MYC are found co-deregulated in human B and plasma-cell cancers. In physiology, NF-{kappa}B is necessary for terminal B-to-plasma cell differentiation, whereas MYC repression is required. It is thus unclear if NF-{kappa}B/MYC co-deregulation is developmentally compatible in carcinogenesis and/or impacts cancer cell differentiation state, possibly uncovering unique sensitivities. Using a mouse system to trace cell lineage and oncogene activation we found that NF-{kappa}B/MYC co-deregulation originated cancers with a plasmablast-like phenotype, alike human plasmablastic-lymphoma and was linked to t(8;14)[MYC-IGH] multiple myeloma. Notably, in contrast to NF-{kappa}B or MYC activation alone, co-deregulation rendered cells addicted to IL6 for survival and phenotypic stability. We propose that conflicting oncogene-driven differentiation pressures can be accommodated at a cost in poorly-differentiated cancers. SignificanceOur studies improve the understanding of cancer pathogenesis by demonstrating that co-deregulation of NF-{kappa}B and MYC synergize in forming a cancer with a poorly-differentiated state. The cancers in the mouse system share features with human Plasmablastic lymphoma that has a dismal prognosis and no standard of care, and with t(8;14)[MYC-IGH] Multiple myeloma, which is in overall resistant to standard therapy. Notably, we found that NF-{kappa}B and MYC co-deregulation uniquely render cells sensitive to IL6 deprivation, providing a road-map for patient selection. Because of the similarity of the cancers arising in the compound mutant mouse model with that of human Plasmablastic lymphoma and t(8;14)[MYC-IGH] Multiple myeloma, this model could serve in preclinical testing to investigate novel therapies for these hard-to-treat diseases. HighlightsO_LINF-{kappa}B and MYC co-activation originates (pre)plasmablast-like cancer C_LIO_LINF-{kappa}B/MYC+ renders cancer cells addicted to IL6 for survival and phenotypic stability C_LIO_LINF-{kappa}B/MYC+ cancers are alike a fraction of human plasmablastic lymphoma C_LIO_LIt(8;14)[MYC-IGH] multiple myeloma is linked to a NF-{kappa}B/MYC co-activation signature C_LI

cancer biology↗